← Leaderboards
Kirkwood F Adams
University Of North Carolina Chapel Hill
$4,990,072
Attributed
$4,990,072
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $244K · FY2005–15$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,990,072 · 11
By mechanism
M01$4,284,279 · 10
R34$705,793 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Kathleen C Light$8,355,143
- Michael J Golding$676,049
- Marci K Campbell$7,332,570
- Melinda A. Beck$14,770,532
- Cort A Pedersen$7,997,634
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationCongestive Heart FailureHeart Disorder ChemotherapyCardiovascular AgentsClinical TrialsHeart FailureHuman MortalityPlacebosCardiovascular FunctionQuality Of LifeAntihypertensive AgentsHormone InhibitorCardiovascular Disorder ChemotherapyAmlodipineSign /SymptomCorticotropin Releasing FactorClinical Trial Phase ITrainingOutcomes ResearchHospital UtilizationHeart Ventricle
Grant awards (45)
3/3-Multi-Site - Omega-3 for Co-Morbid Depression & HF Treatment (OCEAN)$230,661
R34 · FY2015 · MH · contact PI
3/3-Multi-Site - Omega-3 for Co-Morbid Depression & HF Treatment (OCEAN)$231,089
R34 · FY2014 · MH · contact PI
3/3-Multi-Site - Omega-3 for Co-Morbid Depression & HF Treatment (OCEAN)$244,043
R34 · FY2013 · MH · contact PI
CLINICAL TRIAL: A CONGESTIVE HEART FAILURE TRIAL INVESTIGATING OUTCOMES OF EXERC$230
M01 · FY2008 · RR · contact PI
A CONGESTIVE HEART FAILURE TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAINING$5,065
M01 · FY2007 · RR · contact PI
A CONGESTIVE HEART FAILURE TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAINING$4,956
M01 · FY2006 · RR · contact PI
ORAL TOLVAPTAN TABLETS IN SUBJECTS HOSPITALIZED WITH WORSENING CHF$248
M01 · FY2006 · RR · contact PI
A CONGESTIVE HEART FAILURE TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAINING$2,514
M01 · FY2005 · RR
CONGESTIVE HEART FAILURE AND PULMONARY ARTERY CATHETERIZATION (ESCAPE)$1,256
M01 · FY2005 · RR
Congestive Heart Failure and Pulmonary Artery Catheterization (ESCAPE)$5,094
M01 · FY2004 · RR
A Congestive Heart Failure Trial Investigating Outcomes of Exercise Training$283
M01 · FY2004 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PATIENTS WITH CHF$190,747
M01 · FY2002 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$190,747
M01 · FY2002 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$190,747
M01 · FY2002 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$190,747
M01 · FY2002 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$190,747
M01 · FY2002 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$294,555
M01 · FY2001 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$294,555
M01 · FY2001 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PATIENTS WITH CHF$294,555
M01 · FY2001 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$294,555
M01 · FY2001 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$294,555
M01 · FY2001 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$190,747
M01 · FY2001 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$190,747
M01 · FY2001 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$190,747
M01 · FY2001 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$190,747
M01 · FY2001 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PATIENTS WITH CHF$190,747
M01 · FY2001 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$294,555
M01 · FY2000 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$294,555
M01 · FY2000 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$294,555
M01 · FY2000 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$241
M01 · FY2000 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$241
M01 · FY2000 · RR
CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL TRIAL$241
M01 · FY2000 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PTS W/ CHF$0
M01 · FY2000 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$0
M01 · FY2000 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$0
M01 · FY2000 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$0
M01 · FY2000 · RR
SINGLES DOSES OF CP 316,311 IN CONGESTIVE HEART FAILURE$0
M01 · FY2000 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$0
M01 · FY2000 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PTS W/ CHF$0
M01 · FY2000 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PTS W/ CHF$0
M01 · FY2000 · RR
PRAISE 2--EFFECT OF AMLODIPINE ON SURVIVAL IN PTS W/ CHF$0
M01 · FY2000 · RR
ORAL YM087 (CI-1025) IN CLASS III CHRONIC HEART FAILURE PTS$0
M01 · FY2000 · RR
HUMAN TUMOR NECROSIS FACTOR RECEPTOR PROTEIN IN CHF$0
M01 · FY2000 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$0
M01 · FY2000 · RR
CP 424 391 IN MEN &WOMEN W/ MILD TO MODERATE HEART FAILURE$0
M01 · FY2000 · RR